In particular, by affecting both the host immune system, via the removal of the barrier induced by immune checkpoints cooperation, and the tumor cell pro-survival pathways, the β3-AR antagonism may represent a promising strategy with, hopefully, therapeutic potential for patients affected by NB malignancies. This evidence concerns the gene ADRB3 and neuroblastoma.